1. Home
  2. ACLS vs PBLS Comparison

ACLS vs PBLS Comparison

Compare ACLS & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Axcelis Technologies Inc.

ACLS

Axcelis Technologies Inc.

HOLD

Current Price

$111.51

Market Cap

3.8B

Sector

Technology

ML Signal

HOLD

Logo Parabilis Medicines Inc. Common Stock

PBLS

Parabilis Medicines Inc. Common Stock

HOLD

Current Price

$25.11

Market Cap

3.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACLS
PBLS
Founded
1995
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
3.6B
IPO Year
2000
2026

Fundamental Metrics

Financial Performance
Metric
ACLS
PBLS
Price
$111.51
$25.11
Analyst Decision
Hold
Strong Buy
Analyst Count
5
5
Target Price
★ $161.00
$41.75
AVG Volume (30 Days)
274.9K
★ 910.8K
Earning Date
11-03-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 1.05
N/A
Revenue
★ $839,048,000.00
N/A
Revenue This Year
$5.30
N/A
Revenue Next Year
$11.91
$222.58
P/E Ratio
$103.03
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$73.60
$22.78
52 Week High
$193.78
$42.49

Technical Indicators

Market Signals
Indicator
ACLS
PBLS
Relative Strength Index (RSI) 39.45 36.35
Support Level $111.80 N/A
Resistance Level $120.96 $41.72
Average True Range (ATR) 5.00 2.31
MACD -2.88 -0.41
Stochastic Oscillator 9.52 28.27

Price Performance

Historical Comparison
ACLS
PBLS

About ACLS Axcelis Technologies Inc.

Axcelis Technologies Inc designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. In addition to equipment, the company provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. Geographically, the group has a business presence in North America, Asia Pacific, and Europe, of which key revenue is derived from the Asia Pacific.

About PBLS Parabilis Medicines Inc. Common Stock

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Share on Social Networks: